Hospital Universitario 12 de Octubre-ko ikertzaileekin lankidetzan egindako argitalpenak (38)

2023

  1. Clinical features and outcomes of acute heart failure in nonagenarians: Results of a nationwide study

    Geriatrics and Gerontology International

  2. Opinion on the 2021 ESC guidelines on heart failure: a cross-sectional survey of 387 doctors

    REC: CardioClinics, Vol. 58, Núm. 1, pp. 7-15

  3. One-year readmissions for circulatory diseases and in-hospital mortality after an index episode of heart failure in elderly patients. A nationwide data from public hospitals in Spain between 2016 and 2018

    Clinical Research in Cardiology

  4. 30-day readmissions for circulatory system diseases in patients over 75 years with heart failure in Spain (2016-2018)

    Revista Espanola de Cardiologia

2022

  1. Statistical Evaluation of Metaproteomics and 16S rRNA Amplicon Sequencing Techniques for Study of Gut Microbiota Establishment in Infants with Cystic Fibrosis

    Microbiology Spectrum, Vol. 10, Núm. 6

  2. Impact of blood pressure on management and prognosis of patients treated with sacubitril/valsartan

    REC: CardioClinics, Vol. 57, Núm. 2, pp. 116-122

2021

  1. Physiopathology, diagnosis, and management of hypomagnesemia in heart failure patients

    REC: CardioClinics

  2. Initiation and titration of sacubitril/valsartan in different types of centers

    REC: CardioClinics, Vol. 56, Núm. 2, pp. 92-97

  3. Effectiveness and safety of a single-dose ivermectin treatment for uncomplicated strongyloidiasis in immunosuppressed patients (Immunostrong study): The study protocol

    Pathogens, Vol. 10, Núm. 7

  4. Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab

    Scientific Reports, Vol. 11, Núm. 1

2020

  1. Staphylococcus epidermidis in feedings and feces of preterm neonates

    PLoS ONE, Vol. 15, Núm. 2

  2. Sacubitril/Valsartan is useful and safe in elderly people with heart failure and reduced ejection fraction. Data from a real-word cohort

    Revista Espanola de Geriatria y Gerontologia, Vol. 55, Núm. 2, pp. 65-69

  3. Long-term docosahexaenoic acid (DHA) supplementation in cystic fibrosis patients: a randomized, multi-center, double-blind, placebo-controlled trial

    Prostaglandins Leukotrienes and Essential Fatty Acids, Vol. 162

  4. Left Ventricular Ejection Fraction Recovery in Patients with Heart Failure and Reduced Ejection Fraction Treated with Sacubitril/Valsartan

    Cardiology (Switzerland), Vol. 145, Núm. 5, pp. 275-282

2019

  1. Sex Influence on the Efficacy and Safety of Sacubitril/Valsartan

    Cardiology (Switzerland), Vol. 142, Núm. 2, pp. 73-78

  2. Serratia marcescens colonization in preterm neonates during their neonatal intensive care unit stay

    Antimicrobial Resistance and Infection Control, Vol. 8, Núm. 1

  3. Safety of sacubitril/valsartan initiated during hospitalization: data from a non-selected cohort

    ESC Heart Failure, Vol. 6, Núm. 6, pp. 1161-1166

  4. In-hospital Mortality and Readmissions for Heart Failure in Spain. A Study of Index Episodes and 30-day and 1-year Cardiac Readmissions

    Revista Espanola de Cardiologia, Vol. 72, Núm. 12, pp. 998-1004

  5. Five year long term result of total joint arthroplasties in the treatment of trapeziometacarpal osteoarthritis

    Acta Biomedica, Vol. 90, Núm. 4, pp. 451-456

2018

  1. Clinical Profile of a Nonselected Population Treated With Sacubitril/Valsartan Is Different From PARADIGM-HF Trial

    Journal of cardiovascular pharmacology, Vol. 72, Núm. 2, pp. 112-116